Žirmūnų psichikos sveikatos centras

Study finds anti-depressants actually change the structure of the brain

Žirmūnų psichikos sveikatos centro naujienos

Scientists have made a startling discovery. According to a new study researchers presented at the 35th Annual European College of Neuropsychopharmacology in Vienna, certain anti-depressants can cause drastic changes in the brain. In fact, they may even be able to rewire brains affected by major depressive disorder.


Major depressive disorder, or MDD as I’ll refer to it from here out, is a mental health disorder that is characterized by persistent depressing moods, dark thoughts, and a general loss of interest in any activities. It can cause major impairment in the daily lives of people affected by it. Now, though, we may be able to treat it by using certain anti-depressants to change how the brain is wired.


In the past, researchers have found that anti-depressants and even behavioral therapy and electroconvulsive therapy just don’t work for everyone that suffers from MDD. However, a group of researchers in Germany are now claiming that anti-depressants can change the brain structures themselves. However, they aren’t sure how long those changes will remain.


Past studies have found that serious bouts of depression are often associated with a change in the volume of gray matter and white matter found within the brain. Each type of brain matter is associated with different functions of the body, and any changes in them can drastically change how our brains react. As such, being able to change the brain’s structure with anti-depressants is huge.

Sad man

And, if we can prove that there is a strong link between the structure of the human brain, and how depressive thoughts function, then it could help improve how we diagnose and treat things like MDD. Right now, though, many disagree on whether that link is consistent or strong enough to utilize in diagnosing and treating disorders like MDD. Researchers in Germany believe it is, though.


In an experiment, the researchers found that out of 109 patients with MDD, the greatest changes in their symptoms came based on how much the anti-depressants and other treatment options changed their brain structures. They also compared the brains of the patients with MDD to those of “healthy” individuals without the disorder.


“We were surprised at the speed of the response,” psychiatrist Jonathan Repple said in a statement. Repple also says that they don’t have an explanation for how or why these changes in the brain take place, or even how anti-depressants and other treatments make those changes.


There are a lot of factors that can come into play when we’re talking about depression. For instance, the amount of daylight you get each day can change your mood drastically. And even being left-handed can increase your chance of mental disorders like MDD. Additionally, some anti-depressants, like a special nose spray, can work faster at causing those changes in the brain.



But, if we can better understand those changes, perhaps we could discover new ways to treat disorders like MDD.

Google Translate
Mediacijos paslaugos
Google Translate
SKIRTINGOS SPALVOS 10 LAIDA - Justės Arlauskaitės-Jazzu istorija (savižudybių prevencija)
16 birž., 2023
Socialinė iniciatyva Skirtingos Spalvos pristato dešimtąją laidą ir jos pašnekovę – Justę Arlauskaitę-Jazzu. Šioje laidoje žinoma atlikėja kalbėjo apie emocinę sveikatą ir savižudybių prevenciją Itin atvirame pokalbyje Justė pasidalijo įvairiomis gyvenimo patirtimis apie santykius su žmonėmis, vaikystėje išmoktas pamokas, ilgai trukusią kovą su priklausomybėmis, panikos atakomis, kelionę sveikimo link ir iš naujo užgimusią Justę, kuomet ant rankų pradėjo sūpuoti savo sūnų Majų. Kaip ir pati Justė laidos metu atviravo, kad gyvenime atlikėja save suprato kaip balsą, o kai jį staiga prarado, nebematė tikslo toliau gyventi, jautėsi nereikalinga nei sau, nei kitiems. Užtruko laiko save susirinkti ir suprasti, kad Justė nėra tik apie balsą. „Pradėjau remtis į kitus žmones, ieškoti pagalbos, kurios nėra gėda ieškoti, tai yra drąsa prašyti pagalbos ir eiti šviesos link“, – atvirauja Justė.
EPA 2023
05 bal., 2023
Kovo 25-28 dienomis Paryžiuje vyko 31- asis Europos psichiatrų kongresas, kuriame dalyvavo du gydytojai psichiatrai iš mūsų centro. Daug naujų tyrimų, gydymo metodų. Kiekvieną dieną buvo skaitoma po 2 pranešimus apie ADHD. Europoje šiam sutrikimui pastaruoju metu skiriamas didelis dėmesys.
Autorius Sergej Spiridonov 27 vas., 2023
Years ago, Big Pharma had all but left psychiatry behind. Having undertaken large, disappointing failed trials they had hoped would lead to new and profitable treatments, big companies folded up their ambitious plans . But smaller biotech companies continued to plug away at research and development, hoping to create better treatments . And now, their labor may be paying off. That's according to Laura Gault, the chief medical officer at Sage Therapeutics, a Massachusetts-based company working to develop a new antidepressant drug, called zuranolone. The company recently asked US regulators to approve the drug as a treatment for people with postpartum depression and major depressive disorder, citing data that the drug improved symptoms of those disorders in patients. "Psychiatry is really on the cusp of having novel medicines that are really effective and work in different ways from what we've had," Gault said.
Share by: